A detailed history of E&G Advisors, LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, E&G Advisors, LP holds 301 shares of REGN stock, worth $227,799. This represents 0.09% of its overall portfolio holdings.

Number of Shares
301
Previous 301 -0.0%
Holding current value
$227,799
Previous $316,000 -0.0%
% of portfolio
0.09%
Previous 0.09%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 25, 2024

SELL
$775.18 - $881.7 $3,100 - $3,526
-4 Reduced 1.31%
301 $264,000
Q1 2023

Apr 17, 2023

SELL
$680.49 - $826.97 $3,402 - $4,134
-5 Reduced 1.61%
305 $250,000
Q3 2022

Oct 11, 2022

BUY
$573.97 - $724.32 $177,930 - $224,539
310 New
310 $214,000
Q2 2022

Jul 06, 2022

SELL
$548.35 - $738.84 $169,988 - $229,040
-310 Closed
0 $0
Q1 2022

Apr 12, 2022

BUY
$595.12 - $698.43 $184,487 - $216,513
310 New
310 $217,000
Q3 2021

Oct 20, 2021

SELL
$574.03 - $680.96 $0 - $0
0 Closed
0 $0
Q2 2021

Jul 12, 2021

BUY
$472.8 - $558.54 $0 - $0
0 New
0 $235,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track E&G Advisors, LP Portfolio

Follow E&G Advisors, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E&G Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on E&G Advisors, LP with notifications on news.